This is the authors' abstract. We don't add key points for this paper.
The Atellica® CH 930 is a new biochemistry analyzer recently introduced to the world market. This study aims to compare the Atellica® CH 930 analyzer to the Architect® ci4100 analyzer for measurement of serum aspartate (AST) and alanine (ALT) aminotransferase concentrations. A total of 112 sera were tested on the Architect® ci4100 and the Atellica® CH 930 analyzers for ALT and AST activities, and the results were compared using the paired Student's t-test, Pearson’s correlation analysis, Passing-Bablok regression analysis, and Bland–Altman plots. There was no significant difference between the means of the ALT and AST concentrations measured using the two instruments (p = 0.659 and p = 0.506, respectively). For ALT, the Passing-Bablok equation was Atellica=1.11 ×Architect -0.96, with a correlation coefficient (r) of 0.999. For AST, it was Atellica=1.08 ×Architect -0.50, with r = 0.998. According to Bland-Altman plots, the mean difference between both methods was 2.3 IU/L (4.3%) for ALT and 2.1 IU/L (5.8%) for AST, with 95.53% and 96.43% of points within the interval [0 ± 1.96 × SD], respectively. These findings demonstrated that the Atellica® CH 930 and Architect® ci4100 methods had an overall good agreement in aminotransferase measurement.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nachate et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: